Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aspirin underuse

This article was originally published in The Tan Sheet

Executive Summary

"Improvements in reported aspirin use for cardiovascular prevention were modest in the past decade and substantial treatment gaps have persisted, particularly for moderate-risk patients, including individuals with diabetes," reports Randall Stafford, MD/PhD, Stanford University, at the Society of General Internal Medicine annual meeting in Chicago May 23. Analyzing medical survey data over a 10-year period, Stafford found use by diabetics grew only from 4% to 6% between 1992 and 2001. Among high-risk patients, growth was modest as well, from 21% to 24%. "Targeted interventions may be warranted in patients with diabetes and/or multiple major CHD risk factors, as well as in at-risk subpopulations where aspirin use is lower than average"...
Advertisement
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS096819

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel